Advertisement

Biotherapy

, Volume 1, Issue 3, pp 123–131 | Cite as

Induction of endogenous tumor necrosis factor by OK-432 in ovarian cancer patients with ascites

  • Hidehiro Mori
  • Naoki Itoh
  • Yoshitaka Yamada
  • Teruhiko Tamaya
Article

Abstract

To four ovarian cancer patients with malignant ascites, 10 KE of OK-432 was intraperitoneally administered four times at 2 day intervals for priming, and 40 KE of OK-432 was given on the 13th day after the first injection for triggering. The changes in blood monocyte and peritoneal macrophage levels and the production of tumor necrosis factor (TNF) by blood mononuclear cells (BMCs) and ascitic lymphoid cells (ALCs) were examined. In the two patients in whom TNF was induced in the ascites, TNF production by BMCs and ALCs was noted during priming. After triggering, increases in both the number of peritoneal macrophages and TNF production by ALCs were noted. In the other two patients, in whom TNF was not detected in the ascites, the ratio of peritoneal macrophages to ALCs did not change throughout the study period, and TNF production by the ALCs was not augmented. These findings suggest that OK-432 can exert a primary effect on both peritoneal macrophages and blood monocytes, and that OK-432 triggering can promote an increase in primed peritoneal macrophages and the release of TNF from these cells.

Key words

ascites endogenous induction OK-432 ovarian cancer tumor necrosis factor 

Abbreviations

ALCs

ascitic lymphoid cells

BMCs

blood mononuclear cells

FCS

fetal calf serum

IFN-γ

interferon-γ

i.p.

intraperitoneal

KE

Klinische Einheit

LPS

lipopolysaccharide

PBS

phosphate buffered saline

Su-PS

Su-polysaccharide

TNF

tumor necrosis factor

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Old LJ. Antitumor activity of microbial products and tumor necrosis factor. In: Bonavida B, Gifford GE, Kirchner H, Old LJ, eds. Tumor necrosis factor/cachectin and related cytokines. Basel: Karger, 1988: 7–19.Google Scholar
  2. 2.
    Nakano K, Abe S, Sohmura Y. Recombinant human tumor necrosis factor — 1. Cytotoxic activity in vitro. Int J Immunopharmac 1986; 8: 347–55.Google Scholar
  3. 3.
    Sohmura Y, Nakata K, Yoshida H, Kashimoto S, Matsui Y, Furuichi H. Recombinant human tumor necrosis factor — II. Antitumor effect on murine and human tumors transplanted in mice. Int J Immunipharmac 1986; 8: 357–68.Google Scholar
  4. 4.
    Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB. Cloning and expression of the gene for human tumor necrosis factor. Nature (Lond.) 1985; 313: 803–6.Google Scholar
  5. 5.
    Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF. Molecular cloning and expression of human tumor necrosis factor. Science 1985; 228: 149–54.PubMedGoogle Scholar
  6. 6.
    Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986–9.PubMedGoogle Scholar
  7. 7.
    Taguchi T, Kimoto Y, Tanji Y. Clinical studies of recombinant human tumor necrosis factor. In: Bonavida B, Gifford GE, Kirchner H, Old LJ, eds. Tumor necrosis factor/cachectin and related cytokines. Basel: Karger 1988: 196–204.Google Scholar
  8. 8.
    Kato M, Kakehi R, Soma G, Gatanaga T, Mizuno D. Anti-tumour therapy by induction of endogenous tumour necrosis factor. Lancet 1985; ii: 270.Google Scholar
  9. 9.
    Watanabe N, Niitsu Y, Sone H, Neda H, Urushizaki I, Yamamoto A, Nagamuta M, Sugawara Y. Therapeutic effect of endogenous tumor necrosis factor on ascites Meth A sarcoma. J Immunopharmac 1986; 8: 271–83.Google Scholar
  10. 10.
    Satoh M, Inagawa H, Shimada Y, Soma G, Oshima H, Mizuno D. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin. J Biol Resp Mod 1987; 10: 512–24.Google Scholar
  11. 11.
    Kokunai I, Shimano T, Sekimoto K, Takeda T, Kobayashi T, Yayoi E, Yamamoto A, Mori T. Induction of tumor necrosis factor by administration of OK-432 in cancer patients. J Clin Lab Immunol 1986; 21: 169–71.PubMedGoogle Scholar
  12. 12.
    Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I. Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunipharmacology 1986; 11: 79–86.Google Scholar
  13. 13.
    Chang TW, McKinney S, Liu V, Kung PC, Vilcek J, Le J. Use of monoclonal antibodies as sensitive and specific probes for biologically active humanγ-interferon. Proc Natl Acad Sci USA 1984; 81: 5219–22.PubMedGoogle Scholar
  14. 14.
    Ohkaru Y, Sunahara N, Kurooka S. Characterization of monoclonal antibody to PT-050 and its application to enzyme-immunoassay. Proc Jpn Cancer Assoc 44th Annu Meet 1985; 306.Google Scholar
  15. 15.
    Yamazaki S, Onishi E, Enami K, Natori K, Kohase M, Sakamoto H, Tanouchi M, Hayashi H, Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jap J Med Sci Biol 1986; 39: 105–118.PubMedGoogle Scholar
  16. 16.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson BD. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–70.PubMedGoogle Scholar
  17. 17.
    Pace JL, Russell SW, Toress BA, Johnson HM, Gray PW. Recombinant mouseγ-interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 1983; 130: 2011–3.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Hidehiro Mori
    • 1
  • Naoki Itoh
    • 1
  • Yoshitaka Yamada
    • 2
  • Teruhiko Tamaya
    • 1
  1. 1.Department of Obstetrics and GynecologyGifu University School of MedicineGifu
  2. 2.Department of Obstetrics and GynecologyGifu Prefectural Gifu HospitalGifuJapan

Personalised recommendations